These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 15199272)
1. Hereditary breast and ovarian cancer: what the primary care physician should know. Khoury-Collado F; Bombard AT Obstet Gynecol Surv; 2004 Jul; 59(7):537-42. PubMed ID: 15199272 [TBL] [Abstract][Full Text] [Related]
5. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Shulman LP Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261 [TBL] [Abstract][Full Text] [Related]
6. Risk management options elected by women after testing positive for a BRCA mutation. Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485 [TBL] [Abstract][Full Text] [Related]
7. Prophylactic surgery in hereditary breast/ovarian cancer syndrome. Levine DA; Gemignani ML Oncology (Williston Park); 2003 Jul; 17(7):932-41; discussion 946-8, 950-2. PubMed ID: 12886864 [TBL] [Abstract][Full Text] [Related]
8. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Nelson HD; Pappas M; Cantor A; Haney E; Holmes R JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902 [TBL] [Abstract][Full Text] [Related]
9. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Moyer VA; Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376 [TBL] [Abstract][Full Text] [Related]
10. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Nelson HD; Huffman LH; Fu R; Harris EL; Ann Intern Med; 2005 Sep; 143(5):362-79. PubMed ID: 16144895 [TBL] [Abstract][Full Text] [Related]
11. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
12. [Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers]. Llort G; Peris M; Blanco I Med Clin (Barc); 2007 Mar; 128(12):468-76. PubMed ID: 17408542 [TBL] [Abstract][Full Text] [Related]
13. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168 [TBL] [Abstract][Full Text] [Related]
14. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. Schrag D; Kuntz KM; Garber JE; Weeks JC JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701 [TBL] [Abstract][Full Text] [Related]
15. Management updates for women with a BRCA1 or BRCA2 mutation. Nusbaum R; Isaacs C Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734 [TBL] [Abstract][Full Text] [Related]
16. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
17. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests. Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829 [TBL] [Abstract][Full Text] [Related]
18. Management of hereditary breast and ovarian cancer. Yamauchi H; Takei J Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095 [TBL] [Abstract][Full Text] [Related]
19. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675 [TBL] [Abstract][Full Text] [Related]
20. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]